---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-003621"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:59:44.403530+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AVITA reports preliminary FY2023 revenue $49.8M (+46% YoY), signs PermeaDerm distribution deal

## Summary
- Q4 2023 commercial revenue ~$14.1M (+50% YoY); full-year 2023 commercial revenue ~$49.8M (+46% YoY).
- FY2023 gross margin ~84.5%; cash, equivalents and marketable securities ~$89.1M as of Dec 31, 2023.
- FY2024 revenue guidance $78.5M–$84.5M (+57%–69% YoY); Q1 2024 guidance $14.8M–$15.6M (+42%–50% YoY).
- Exclusive multi-year distribution agreement with Stedical Scientific for PermeaDerm in the US; 5-yr initial term, 50% gross margin on sales.
- Completed enrollment in TONE post-market vitiligo study (109 patients); 12-month follow-up with 6-month primary endpoint.

## SEC filing metadata
- accession: 0000950170-24-003621
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/0000950170-24-003621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/rcel-20240110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-003621
- JSON: https://secwatch.observer/filing/0000950170-24-003621.json
- Plain text: https://secwatch.observer/filing/0000950170-24-003621.txt

## Key facts
- Earnings Releases
  AVITA Medical, Inc. reported first quarter and full-year 2024 results: revenue range of $14.8 to $15.6 million and $78.5 to $84.5 million. Guidance reaffirmed.
  - Period: first quarter and full-year 2024
  - Revenue: range of $14.8 to $15.6 million and $78.5 to $84.5 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: committed to sustaining growth and building our business in 2024.” 2024 Financial Guidance • Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million, reflecting growth at the lower bound of approximately 42% and upper bound of approximately 50% over the same period in the prior year • Commercial revenue for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/0000950170-24-003621-index.htm
- Earnings Releases
  AVITA Medical, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue approximately $14.1 million and approximately $49.8 million.
  - Period: fourth quarter and full-year ended December 31, 2023
  - Revenue: approximately $14.1 million and approximately $49.8 million
  - Result: preliminary results
  source text: its post-market study, TONE. Preliminary Fourth Quarter and Full-Year 2023 Financial Highlights • Commercial revenue for the fourth quarter 2023 is expected to be approximately $14.1 million, an increase of approximately 50% compared to same period in 2022 • Commercial revenue for the full-year 2023 is expected to be approximately $49.8 million, an increase of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/0000950170-24-003621-index.htm
- Material Agreements
  AVITA Medical, Inc. entered into Distribution Agreement with Stedical Scientific, Inc. valued at Exclusive distribution of PermeaDerm Biosynthetic Wound Matrix in the US; initial 5-year term with a (effective 2024-01-10).
  - Action: entry
  - Agreement: supply
  - Counterparty: Stedical Scientific, Inc.
  - Value: Exclusive distribution of PermeaDerm Biosynthetic Wound Matrix in the US; initial 5-year term with a
  - Effective: 2024-01-10
  source text: On January 10, 2024, AVITA Medical Americas LLC (“AVITA Americas”), a wholly-owned subsidiary of AVITA Medical, Inc., (the “Company”) entered into an exclusive multi-year distribution agreement (“Agreement”) with Stedical Scientific, Inc. (“Stedical Scientific”) to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/0000950170-24-003621-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.